title: Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
abstract: Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. usandkovsky@unmc.edu
authors.forename: Uriel
authors.initials: U
authors.lastname: Sandkovsky
authors.forename: Susan
authors.initials: S
authors.lastname: Swindells
authors.forename: Brian L
authors.initials: BL
authors.lastname: Robbins
authors.forename: Sarah R
authors.initials: SR
authors.lastname: Nelson
authors.forename: Edward P
authors.initials: EP
authors.lastname: Acosta
authors.forename: Courtney V
authors.initials: CV
authors.lastname: Fletcher
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006679:HIV Seropositivity / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007963:Leukocytes, Mononuclear; D008297:Male; D011446:Prospective Studies; D011760:Pyrrolidinones / Q000097:blood / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium